This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wang, X. Articles by Li, J. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Li, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dialysis Dietary Fats Social Bookmarking                   What's this?

-3 Fatty Acids–Supplemented Parenteral Nutrition Decreases Hyperinflammatory Response and Attenuates Systemic Disease Sequelae in Severe Acute Pancreatitis: A Randomized and Controlled Study

From the Research Institute of General Surgery, Jinling Hospital, Nanjing, China.

Address correspondence to: Jieshou Li, MD, Research Institute of General Surgery, Jinling Hospital, 305 Zhongshan East Road, Nanjing, 210002, China; e-mail: wxinying{at}263.net.

Background: The objective of this study was to investigate whether altering the fatty acid (FA) profile by -3 FA supplementation affects inflammatory response and systemic disease sequelae in severe acute pancreatitis. Methods: Forty severe acute pancreatitis patients were enrolled and randomly assigned to receive parenteral nutrition (PN) for 5 days in a double-blind manner. Patients received PN with identical amounts of amino acids (1.25 g/kg/d), glucose (3 g/kg/d), and fat (1 g/kg/d) but different lipid compositions: the control group received a soybean oil (SO; Lipovenos 20%; Fresenius, Germany)–based fat solution and the -3 FA group was supplemented with 0.15 - 0.2 g/kg/d fish oil (FO; Omegaven 10%; Fresenius, Germany). Serum concentrations of eicosapentaenoic acid (EPA), interleukin-6, C-reactive protein (CRP), white blood cell count, and routine respiratory and renal parameters were measured before PN, and again on day 6 after starting PN. Outcomes such as infection morbidity, mortality, intensive care unit time, and length of hospital stay were recorded. Results: Patients treated with FO had a significantly higher EPA concentration (P < .01), lower CRP level (P < .05), and better oxygenation index (P < .05) after 5 days of PN. Moreover, the number of days of continuous renal replacement therapy (CRRT) in the -3 FAs group was significantly less than that in the control group (P < .05). Conclusions: PN supplemented with -3 FAs diminishes the hyperinflammatory response by the EPA increase and the proinflammatory cytokine decrease in severe acute pancreatitis. This, together with improved respiratory function and shortened CRRT time, suggests that the systemic response to pancreatic and organ injury is attenuated.

Key Words: -3 fatty acids • severe acute pancreatitis • fish oil • inflammatory response • respiratory function • fatty acids • pancreatic disease • lipids

The systemic inflammatory response appears in the early phase of severe acute pancreatitis (SAP), which is determined by pancreatic and peripancreatic necrosis. Exacerbation of the systemic inflammatory response results in immune function paralysis and life-threatening complications, even multiple organ failure. Therefore, attempts to reduce the excessive inflammatory response in SAP, for example, by blocking certain proinflammatory cytokines or secondary mediators involved in these reactions, are important.^1-4 However, there is no good strategy to attenuate the inflammatory response to date. Thus, it is necessary to find a new pathway to decrease hyperinflammation in SAP patients.

It is widely accepted that long-chain polyunsaturated fatty acids (PUFAs) not only provide energy but also possess important additional functions. While -6 fatty acids (FAs) have been demonstrated to enhance the inflammatory response, -3 FAs have been observed to suppress inflammation and ameliorate the course of infection, such as sepsis, ulcerative colitis, and acute respiratory distress syndrome.^4-12 In general, eicosanoids derived from -3 FAs cause biologic responses opposite to those of -6 FAs, including less inflammatory response after trauma or surgery. These data indicate that these fatty acids have potential clinical benefit for patients undergoing intensive care.

Meanwhile, patients often need parenteral nutrition (PN) in the early phase of SAP because of increased metabolic demand or the presence of ileus. However, it is unclear whether addition of -3 FAs to PN influences inflammatory response in SAP patients. Thus, we designed a randomized, double-blind, and controlled study to compare the effects of -3 and -6 FAs emulsions in PN on the hyperinflammatory response and systemic disease sequelae in SAP patients. In the present study, we used soybean oil (SO) and fish oil (FO) emulsions as major sources of -6 and -3 FAs, respectively.

	Methods

Top Methods Results Discussion

 
Patients
Forty patients suffering from severe acute pancreatitis were enrolled between April 2006 and February 2007. The inclusion criteria were based on the Summary of the International Symposium on Acute Pancreatitis, Atlanta, 1992. Acute pancreatitis is an acute inflammatory process of the pancreas, with variable involvement of other regional tissues or remote organ systems. Moreover, severe acute pancreatitis is associated with organ failure and/or local complications, such as necrosis, abscess, or pseudocyst.¹³ Patient characteristics are shown in Table 1. The study was approved by the Ethics Committee of the medical faculty of Jinling Hospital, and the followed procedures were in accordance with the Helsinki Declaration of 1975, as revised in 1989. Voluntary informed consent of each patient was obtained before the commencement of the investigation. Patients were enrolled within 72 hours after onset of SAP and were randomized to receive PN supplemented with either SO or SO-FO emulsion in a double-blind manner (Table 2). Patients were 18 - 80 years old before entry to the study. The patients were observed for 5 days in the 17-bed intensive care unit (ICU) of the Department of General Surgery.^6,7

Exclusion Criteria
Patients were excluded if admitted to the hospital after 72 hours of SAP onset. Patients who were pregnant, underweight or obese (body mass index <16 or >30 kg/m²), or those with known alcohol or drug abuse were excluded from participation. Patients with hypertriglyceridemia, hyperthyroidism, chronic liver disease, HIV infection, hepatitis, severe cardiac or renal disease, or the use of insulin, corticoids, cytostatics, or cyclooxygenase inhibitors within 2 weeks prior to the study were also excluded.

Double Blinding and Randomization
Patients were assigned to the respective group by computerderived block randomization. The nurse was the only person aware of the randomization list. Accordingly, she prepared solutions in the Nutrition Center of Jinling Hospital for each patient. PN was then delivered blindly (with patient identification) to the ICU and further handled by a nurse who was unaware of the study protocol. Thus, the investigators were blinded to the infused drugs.

Nutrition Interventions
It was reported that -3 FAs–supplemented fat emulsion in PN for 5 days after surgery was clinically safe and led to alteration of the FA profile in plasma and attenuation of inflammation. Patients were randomly assigned to the 2 groups to receive isonitrogenous (0.2 g N/kg/d) and isoenergetic (117 kJ/28 kcal/kg/d) PN. The PN formula is shown in Table 2. It was administered by an indwelling central venous catheter. The regimen consisted of 1.25 g of amino acids/kg/d, 3 g of glucose/kg/d, and 1 g of fat/kg/d. Lipid was either SO (Lipovenos 20%; Fresenius, Germany) or FO-supplemented SO (Omegaven 10%; Fresenius, Germany). In the SO-FO group, the -6 FAs content of PN was partially replaced by -3 FAs up to 10 g daily, about 0.15 - 0.2 g/kg body weight, which was the recommended daily dosage. Thus, the -3/-6 FAs ratio was about 1:4 in the SO-FO group. A previous report found that this dosage was associated with attenuated inflammatory response.¹² Moreover, the daily regimen contained fat-soluble (Vitalipid; Fresenius, Germany) and water-soluble (Soluvit; Fresenius, Germany) vitamins as well as trace elements (Addel N; Fresenius, Germany). No enteral or oral food intake was permitted in the 5 days.

Samples
On day 1 of PN, baseline values were obtained before PN was started (8:00 AM), including blood samples. Then, blood samples were collected on day 6 after the completion of PN. For laboratory measurements, 15 mL of whole blood was withdrawn from an arterial line. Serum vials for analysis of cytokines were separated and kept deep frozen at –80°C until measurement. Another group of blood samples was used to analyze plasma FA composition with high-performance gas chromatography.

Inflammatory Response
During the treatment course, vital signs were recorded, including heart rate, blood pressure, respiration rate, body temperature, and other clinical parameters. White blood cell count and serum C-reactive protein (CRP) were also measured. The plasma level of interleukin (IL)–6 was quantified with an enzyme-linked immunosorbent assay (Jinmei Corp, Shanghai, China).

The ratio of systemic inflammatory response syndrome (SIRS) was recorded before and after PN in both groups. In 1992, SIRS was first defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. SIRS represents a hypermetabolic phase and dropout release of various proinflammatory factors. It typically has 2 or more of the 4 clinical findings: (1) white blood cell count >12,000 cells/mm³ or <4000 cells/mm³ or >10% immature forms, (2) body temperature >38°C or <36°C, (3) heart rate >90 beats per minute, and (4) respiratory rate >20 breaths per minute or PaCO₂ <4.3 KPa. The SIRS score equals the number of clinical findings.¹⁴

Organ Function
Pulmonary function was measured by arterial blood gas to obtain the oxygenation index. The oxygenation index is the arterial oxygen pressure (PaO₂) divided by FiO₂. A SAP patient was considered to have acute respiratory distress syndrome (ARDS) if the PaO₂:FiO₂ ratio was <200 and there was a diffuse infiltrate (3 quadrants or more) on x-ray. In addition, there could be no evidence of a pulmonary capillary wedge pressure of >2.4 kPa (18 mm Hg).¹⁵

Acute kidney injury is defined as an abrupt (within 48 hours) reduction in kidney function. The criteria include an absolute increase in serum creatinine of 0.3 mg/dL (26.4 µmol/L), a percentage increase in serum creatinine of 50% (1.5-fold from baseline), or reduced urine output (documented oliguria of <0.5 mL/kg/h for > 6 hours). In SAP patients, the indications for continuous renal replacement therapy (CRRT) were acute kidney injury, metabolic acidosis, hyperkalemia, and so on.¹⁶

View larger version (12K): [in this window] [in a new window]   Figure 1. Eicosapentaenoic acid content in plasma in severe acute pancreatitis patients in the control (n = 20) and -3 fatty acid (n = 20) groups. *P < .01, day 6 vs day 1. FO, fish oil; SO, soybean oil.

Statistical Analysis
Values are presented as the mean ± SEM. Statistical analysis was performed by univariate ANOVA followed by a paired t test and Fisher exact test, only when the ANOVA was significant. SPSS 11.0 was used to perform the statistical analysis. P values <.05 were considered statistically significant.

	Results

Top Methods Results Discussion

 
Patients
A total of 40 patients were included. The study was performed with 20 participants receiving the FO-supplemented fat emulsion (-3 FAs group) and 20 participants receiving the SO fat emulsion (control group). The PN was very well tolerated in all SAP patients in the 2 treatment groups. The distribution of age, gender, nutrition status, and the severity of SAP was comparable among the 2 groups (Table 1).

The Change of Plasma FA Profile
After 5 days of PN, there was a significant increase (P < .01) of eicosapentaenoic acid (EPA) content in the plasma in the FO-supplemented PN group but not in the control group (Figure 1).

View larger version (23K): [in this window] [in a new window]   Figure 2. Changes of interleukin (IL)–6 concentration in the plasma of severe acute pancreatitis patients in both groups. The patients were divided into 2 groups: the -3 fatty acid group (n = 20) and the control group (n = 20). FO, fish oil.

White blood cell count and CRP concentration before PN were not different between the 2 groups. The peak of CRP concentration was reached before initiating PN. The mean level was 165 mg/L (range, 60-264 mg/L) in the control group and 177 mg/L (range, 77-229 mg/L) in the -3 FAs group. After 5 days of PN, decreases in CRP concentration in both groups were statistically significant as compared with those on day 1 (P < .05). Moreover, reduction of CRP concentration was greater in the -3 FAs group than in the control group (P < .05; Figure 3). White blood cell counts were reduced from 14.16 ± 0.98 x 10⁹/L to 13.22 ± 1.14 x 10⁹/L in the control group, and from 15.09 ± 1.34 x 10⁹/L to 12.49 ± 1.14 x 10⁹/L in the -3 FAs group on day 6 after PN. However, these decreases were not significantly different between the 2 groups (Table 3).

View larger version (21K): [in this window] [in a new window]   Figure 3. The level of C-reactive protein (CRP) in severe acute pancreatitis patients supplied with parenteral nutrition between the 2 groups. *P < .05, day 6 vs day 1. #-3 fatty acids group (n = 20) vs control group (n = 20). FO, fish oil.

The incidence of SIRS before PN were not different between the 2 groups (20/20 in both groups). After 5 days of PN, the incidence decreased significantly in both groups, with a pronounced decrease in the -3 FAs group but without a statistically significant difference compared with the control group (16/20 vs 11/20; Table 4).

Organ Dysfunction
The incidence of ARDS before PN in the 2 groups, which were measured to elucidate respiratory dysfunction in the acute phase of SAP, were not different between the 2 groups (14/20 in the -3 FAs group vs 13/20 in the control group). However, there were significant decreases in respiratory morbidity in both groups after PN infusion, and these decreases were not significantly different between the 2 groups. In addition, oxygenation indexes increased significantly in both groups from day 1 to day 6. We observed the favorable effect of FO on the lung, as documented by a significantly greater improvement of the oxygenation index after 5 days of FO-SO emulsion (P < .05; Table 4).

The morbidity of acute renal injury in SAP patients of the 2 groups was not significantly different (3/20 in the control group vs 2/20 in the -3 FAs group). However, the number of days of CRRT in the -3 FAs group was less than that in the control group (18 ± 2.3 days vs 26 ± 3.4 days, P < .05; Table 4).

Outcome Measurements
All SAP patients were followed up for 1 month after discharge. In the control group, there were 5 patients with infectious complications (2 abscesses, 2 pneumonia, 1 wound infection), whereas 3 patients with infection (1 abscess, 1 pneumonia, 1 wound infection) were observed in the -3 FAs group.

There were no deaths in the -3 FAs group, whereas 2 patients died in the control group: 1 from multiple organ failure as a consequence of severe abdominal infection and the other from abdominal compartment syndrome after abdominal hemorrhage. All the other patients were transferred to general wards after ICU discharge.

The average ICU stay (21.4 ± 4.2 days in the -3 FAs group vs 27.5 ± 5.6 days in the control group) and hospital stay (65.2 ± 7.3 days in the -3 FAs group vs 70.5 ± 9.1 days in the control group) were not significantly different between the 2 groups.

	Discussion

Top Methods Results Discussion

 
In the cascade of inflammatory response in the acute phase of SAP, there are treatment options for patients with SIRS or sepsis complicated by multiple organ failure. PN supplemented with -3 FAs is one of the strategies. -3 FAs in PN could compete with -6 FAs to change the composition of FAs in plasma. EPA, an -3 PUFA derived from FO, can rapidly incorporate into cell membrane phospholipids, replacing arachidonic acid as a substrate and converting into prostaglandin 3 (PG3) and leukotriene 5 (LT5) series.¹⁷ In the present study, we investigated the changes of plasma FA compositions in SAP patients and found an increased EPA concentration after 5 days of PN supplemented with -3 FAs.^18,19 While -6 FAs have been demonstrated to enhance the inflammatory response and suppress host immunity through the production of potent inflammatory mediates such as prostaglandin 2 (PG2) and leukotriene 4 (LT4) series, -3 FAs are supposed to suppress inflammation and ameliorate the course of infection by reduction of proinflammatory eicosanoids and cytokines.^5-7

De Caterina et al²⁰ demonstrated that consumption of EPA decreased IL-6 and IL-8 in response to IL-1, tumor necrosis factor, or bacterial endotoxin. SAP can lead to a profound systemic inflammatory response. The hallmark of this response was activation of the acute phase through cytokines such as IL-6. In the -3 FAs group, we did find the decreased IL-6 level after PN emulsion, indicating a diminished inflammatory response. However, IL-6 levels increased in the control group. In theory, the modulation of eicosanoid and cytokine biology by the -3 FAs provides an intervention strategy for reducing the hyperinflammatory response so that eicosanoids and cytokines express beneficial effects rather than potentially damaging properties in SAP patients.^21,22 Similar results were also observed in other reports.^8,23,24

The question might be raised as to whether this treatment provided beneficial outcomes in SAP patients. Forty SAP patients were included, and 20 patients receiving supplemental FO did exhibit a significantly faster reduction in CRP level and in SIRS in the initial phase of SAP. We presume this reduction of hyperinflammation in SAP patients was at least partly due to the increase of fewer inflammatory mediators such as EPA in plasma and attenuation of IL-6. It can be deduced that -3 FAs were anti-inflammatory lipids in SAP. Addition of FO may reduce the massive augmentation of the inflammatory response by -6 FA–based lipid emulsions and thereby preserve the inflammatory capacity and avoid substantial damage to organ function in SAP.

There was a greater increase in the oxygenation index after treatment with PN supplemented with -3 FAs treatment, showing that the respiratory function was improved in the -3 FAs group. In addition, the CRRT time was shorter in SAP patients with acute renal failure after -3 FAs supplementation compared with that after -6 FAs treatment, which indicated less damage to renal function. Although there were no significant differences of infection rate, ICU days, or length of hospital stay between the 2 groups, the trend of better clinical outcome with -3 FAs in SAP patients was observed in the present study.

In conclusion, our study shows that attenuation of the hyperinflammatory response can be obtained by -3 FAs supplementation, which changes plasma EPA concentration and decreases proinflammatory cytokines in severe acute pancreatitis. This, together with decreased SIRS ratio and improved respiratory and renal function, suggests that the systemic inflammatory response and other organ injury are attenuated. -3 FAs supplementation may thus be another tool for optimizing therapy in SAP that requires further experimental studies and clinical trials.

Top Methods Results Discussion

 
Financial disclosure: This work was supported by the National Natural Science Foundation of China (30500404).

Received for publication April 28, 2007. Accepted for publication January 2, 2008.

1. Denham W, Norman J. The potential role of therapeutic cytokine manipulation in acute pancreatitis. Surg Clin North Am. 1999;79:767 -781.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
2. Hughes CB, Grewal HP, Gaber LW, et al. Anti-TNFalpha therapy improves survival and ameliorates the pathophysiologic sequelae in acute pancreatitis in the rat. Am J Surg.1996; 171:274 -280.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
3. Kingsnorth AN, Galloway SW, Formela LJ. Randomized double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg.1995; 82:1414 -1420.[Web of Science][Medline] [Order article via Infotrieve]
4. Foitzik T, Eibl G, Hotz HG, et al. Endothelin receptor blockade in severe acute pancreatitis leads to systemic enhancement of microcirculation, stabilization of capillary permeability, and improved survival rates. Surgery. 2000;128:399 -407.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
5. Foitzik T, Eibl G, Schneider P, Wenger FA, Jacobi CA, Buhr HJ. Omega-3 fatty acid supplementation increases anti-inflammatory cytokines and attenuates systemic disease sequelae in experimental pancreatitis. JPEN J Parenter Enteral Nutr.2002; 26:351 -356.[Abstract/Free Full Text]
6. Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol.2003; 171:4837 -4843.[Abstract/Free Full Text]
7. Blok WL, Katan MB, Meer JW. Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr.1996; 126:1515 -1533.[Abstract/Free Full Text]
8. Heller AR, Rössler S, Litz RJ, et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006;34:972 -979.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
9. Jolliet P, Pichard C. Immunonutrition in the critically ill. Intensive Care Med.1999; 25:631 -633.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
10. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med. 1999;27:2799 -2805.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
11. Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lippert H. Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr.2002; 87(Suppl 1):S89 -S94.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
12. Tsekos E, Reuter C, Stehle P, Boeden G. Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin Nutr.2004; 23:325 -330.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
13. Bradley EL III. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg.1993; 128:586 -590.[Abstract/Free Full Text]
14. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest.1992; 101:1644 -1655.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
15. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med.1994; 20:225 -232.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
16. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care.2007; 11:R31 .[CrossRef][Medline] [Order article via Infotrieve]
17. Lee TH, Hoover RL, Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med. 1985;312:1217 -1224.[Abstract]
18. Sprague RS, Stephenson AH, Dahms TE, Lonigro AJ. Proposed role for leukotrienes in the pathophysiology of multiple systems organ failure. Crit Care Clin.1989; 5:315 -329.[Web of Science][Medline] [Order article via Infotrieve]
19. Kinsella JE, Lokesh B, Broughton S, Whelan J. Dietary polyunsaturated fatty acids and eicosanoids. Potential effects on the modulation of inflammatory and immune cells: an overview. Nutrition. 1990;6:24 -44.[Medline] [Order article via Infotrieve]
20. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr.2000; 71(1 Suppl):213S -223S.[Abstract/Free Full Text]
21. Davis JM, Yurt RW, Barie PS, et al. Leukotriene B4 generation in patients with established pulmonary failure. Arch Surg. 1989;124:1451 -1455.[Abstract/Free Full Text]
22. Jolly CA, Jiang YH, Chapkin RS, McMurray DN. Dietary (n-3) polyunsaturated fatty acids suppress murine lymphoproliferation, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. J Nutr. 1997;127:37 -43.[Abstract/Free Full Text]
23. Endres S, Meydani SN, Chorbani R, Schindler R, Dinarello CA. Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol. 1998;54:599 -608.
24. Nohe B, Johannes T, Dieterich HJ. Antiinflammatory effects of omega-3 fatty acids vary at different stages of inflammation. Am J Physiol Heart Circ Physiol.2003; 285:H2248 -H2249.[Free Full Text]

Journal of Parenteral and Enteral Nutrition, Vol. 32, No. 3, 236-241 (2008)
DOI: 10.1177/0148607108316189


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. W. Fetterman Jr. and M. M. Zdanowicz Therapeutic potential of n-3 polyunsaturated fatty acids in disease Am. J. Health Syst. Pharm., July 1, 2009; 66(13): 1169 - 1179. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wang, X. Articles by Li, J. Search for Related Content PubMed PubMed Citation Articles by Wang, X. Articles by Li, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Dialysis Dietary Fats Social Bookmarking                   What's this?